| P2093 | author name string | Eswar Krishnan | |
| P2860 | cites work | Diagnosis and classification of diabetes mellitus | Q24654162 |
| | SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout | Q28119164 |
| | Gout and the risk of acute myocardial infarction | Q28199792 |
| | The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE> | Q28204197 |
| | Risk stratification after acute myocardial infarction | Q28319866 |
| | A modified poisson regression approach to prospective studies with binary data | Q29615575 |
| | Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial | Q31129762 |
| | Hyperuricemia and incident heart failure | Q33572047 |
| | Hyperuricemia and the risk for subclinical coronary atherosclerosis--data from a prospective observational cohort study | Q33875877 |
| | Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. | Q33895894 |
| | Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study | Q34191904 |
| | Purine-rich foods, dairy and protein intake, and the risk of gout in men. | Q34304862 |
| | High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid | Q34585155 |
| | The Natural History of Congestive Heart Failure: The Framingham Study | Q34701680 |
| | Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study | Q35579735 |
| | Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts | Q35773194 |
| | A systematic review and meta-analysis of studies comparing readmission rates and mortality rates in patients with heart failure | Q35959146 |
| | Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure | Q36846087 |
| | Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice | Q37029569 |
| | Absolute and attributable risks of heart failure incidence in relation to optimal risk factors | Q37087291 |
| | Left ventricular hypertrophy and renin-angiotensin system blockade | Q37482193 |
| | Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout | Q37702650 |
| | Long-term cardiovascular mortality among middle-aged men with gout | Q38390010 |
| | Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements | Q39605651 |
| | Gout, allopurinol use, and heart failure outcomes | Q42942195 |
| | Association between allopurinol and mortality in heart failure patients: a long-term follow-up study | Q43289667 |
| | The progression from hypertension to congestive heart failure | Q43812016 |
| | Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies | Q44015014 |
| | Allopurinol improves endothelial dysfunction in chronic heart failure | Q44053746 |
| | Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee | Q45002081 |
| | Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence | Q45166650 |
| | Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study | Q46543475 |
| | Gout in ambulatory care settings in the United States | Q46764565 |
| | Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells | Q46776017 |
| | Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study | Q48491751 |
| | Predictors of prognosis in patients with stable mild to moderate heart failure. | Q49107727 |
| | Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. | Q51575644 |
| | Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. | Q52429603 |
| | Association of Parental Heart Failure with Risk of Heart Failure in Offspring | Q57073040 |
| | Association between C-reactive protein and features of the metabolic syndrome: a population-based study | Q57192740 |
| | Allopurinol Normalizes Endothelial Dysfunction in Type 2 Diabetics With Mild Hypertension | Q61831037 |
| | Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout | Q68197261 |
| | Gout and coronary heart disease: the Framingham Study | Q68259225 |
| | Purine efflux after cardiac ischemia: relevance to allopurinol cardioprotection | Q69741407 |
| | Echocardiographic detection of pressure-overload left ventricular hypertrophy: effect of criteria and patient population | Q70028395 |
| | Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients | Q73532066 |
| | An approach to longitudinal studies in a community: the Framingham Study | Q76476576 |
| | Uric acid in chronic heart failure: a marker of chronic inflammation | Q77788323 |
| | Oxipurinol: alloxanthine, Oxyprim, oxypurinol | Q80079077 |
| | Independent impact of gout on mortality and risk for coronary heart disease | Q80795931 |
| P433 | issue | 1 | |
| P921 | main subject | systole | Q496359 |
| | heart failure | Q181754 |
| P304 | page(s) | e000282 | |
| P577 | publication date | 2012-02-15 | |
| P1433 | published in | BMJ Open | Q17003470 |
| P1476 | title | Gout and the risk for incident heart failure and systolic dysfunction | |
| P478 | volume | 2 | |